




RealRate

PHARMACEUTICAL 2021

Integrated Biopharma INC
Rank 248 of 394

Integrated
BioPharma, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Integrated Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Integrated Biopharma INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Integrated Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 270% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 37% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	16,461
Cost of Goods Sold	46,042
Intangible Assets	0
Liabilities, Current	13,099
Liabilities, Non-Current	3,778
Other Assets	4,787
Other Compr. Net Income	0
Other Expenses	-1,020
Other Liabilities	0
Other Net Income	-171
Other Revenues	52,769
Property and Equipment	1,696
Research and Development	0
Selling, General and Administrative Expense	3,468

Output Variable	Value in 1000 USD
Assets	22,944
Liabilities	16,877
Expenses	48,490
Revenues	52,769
Stockholders Equity	6,067
Net Income	4,108
Comprehensive Net Income	4,108
BaseVar	70,626
ECR before LimitedLiability	87%
Economic Capital Ratio	220%